Objectives Trimethylamine N-oxide (TMAO) is a product of metabolism of
phosphatidylcholine (lecithin) and carnitine by the intestinal microbiome. Elevated serum …

Abstract Background Trimethylamine-N-Oxide (TMAO) is a proatherogenic and
prothrombotic metabolite. Our study examined the association of plasma TMAO level with …

Abstract Trimethlyamine-N-oxide (TMAO) was recently identified as a promoter of
atherosclerosis. Patients with CKD exhibit accelerated development of atherosclerosis; …

Background The microbial metabolite Trimethylamine-N-oxide (TMAO) has been linked to
adverse cardiovascular outcome and mortality in the general population. Objective To …

Cardiovascular disease is more common in patients with chronic kidney disease (CKD), and
traditional risk factors do not adequately predict those at risk for cardiovascular (CV) events …

Rationale: Trimethylamine-N-oxide (TMAO), a gut microbial-dependent metabolite of dietary
choline, phosphatidylcholine (lecithin), and l-carnitine, is elevated in chronic kidney …

Results We observed a wide distribution of serum TMAO in our cohort, with approximately
80% of participants exhibiting TMAO concentrations≥ 56 µM and a maximum TMAO …

Cardiovascular disease causes over 50% of the deaths in dialysis patients, and the risk of
death is higher in white than in black patients. The underlying mechanisms for these findings …

Abstract Purpose of Review Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent
metabolite produced from choline and phosphatidylcholine. Trimethylamine N-oxide was …

Gut microbiota-dependent Trimethylamine-N-oxide (TMAO) has been reported to be strongly
linked to renal function and to increased cardiovascular events in the general population …